tbuckley/cabot-search huggingface dataset:
Cardiovascular Care in Women Veterans
Authors: Janet K. Han, Elizabeth M. Yano, Karol E. Watson, Ramin Ebrahimi
Journal: Circulation (2019)

Cardiovascular disease is the number one cause of death for women in the United States. Of the 1.3 million active duty service members, 16.3% are currently women, and the number of women veterans is expected to increase. Women veterans have higher rates of cardiovascular disease than civilian women and present a unique population. We focus on 5 key areas regarding cardiovascular disease care for women veterans: (1) the rapidly changing demographic; (2) prevalence of traditional risk factors; (3) prevalence of less traditional risk factors (eg, homelessness, military sexual trauma, and mental health disorders); (4) treatment and outcomes of cardiovascular disease; and (5) the current state and future directions of research in this area. This review is a call to action for continued improvements in the cardiovascular care and research for this rapidly growing, at-risk, and under-represented population. Visual Overview: A visual overview is available for this article.
Endothelial Cell-Derived Extracellular Vesicles Mitigate Radiation-Induced Hematopoietic Injury
Authors: Sadhna O. Piryani, Yiqun Jiao, Angel Y.F. Kam, Yang Liu, Tuan Vo-Dinh, Benny J. Chen, Nelson J. Chao, Phuong L. Doan
Journal: Blood (2018)
P133 Clinical and immunological effects of tofacitinib therapy in rheumatoid arthritis
Authors: A Hamar, A Pusztai, E Végh, Á Horváth, K Gulyás, S Szamosi, Z Pethő, N Bodnár, S Szántó, G Szűcs, A Domján, G Nagy, K Hodosi, Z Szekanecz
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Student for a master or a PhD. <h3>Introduction</h3> During the treatment of rheumatoid arthritis (RA) we intend to achieve remission or low disease activity. In this regard, the most effective way is targeted therapy. Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA. <h3>Objectives</h3> The aim of this study was to assess the clinical and immunological effects of one-year tofacitinib therapy in patients with RA. <h3>Methods</h3> Altogether 30 RA patients with active disease were recruited and treated with tofacitinib in this 12 months follow-up study. Mean duration of rheumatoid arthritis were 7.7±5.0 years. Half of the patients haven't received biological treatment prior tofacitinib therapy, other half of the patients switched to tofacitinib therapy after completing washout. 15 patients received 2 × 5 mg and 15 patients received 2 × 10 mg tofacitinib daily for 12 months. Assessments were performed at baseline, month 6 and 12. Levels of CRP and IgM rheumatoid factor (RF) antibodies were measured by quantitaive nephelometry and levels of anti-CCP assesed by ELISA. Lymphocyte subsets (CD3+, CD4+, CD8+ T cells, CD19+ B cells and CD56+/CD3- NK cells) were assesed by cytofluorimetry. In addition, disease activity (DAS28), age and disease duration were also measured. <h3>Results</h3> Tofacitinib therapy was clinically effective, significant improvements in physical function were observed in 26 patients. 4 patients (two from both arms) quit the study due ineffectivity. There were significant decrease in levels of DAS28 (p&lt;0.001), CRP (p&lt;0.001) and HAQ value (p&lt;0.05) in 12 months. There were no changes in levels of RF and anti-CCP. Numbers and ratio of CD3 +and CD4+T cells were significantly decreased (p&lt;0.05), however significant increase was seen in the numbers and ratio of CD19 +B cells after 12 months (p&lt;0.05). There were no significant changes in numbers and ratio of NK cells. There was significant correlation between absolute number of CD8+ T cells and disease duration at baseline (R=0.466, p=0.009). There were no other significant correlations. <h3>Conclusions</h3> One year tofacitinib therapy effectively reduced disease activity and systemic inflammation. The therapy also improved functional capacity. JAK inhibition signficantly decreased the number and ratio of CD3+ and CD4+ T cells and increased number and ratio of CD19+ B cells in 12 months. Tofacitinib is a safe and effective treatment for rheumatoid arthritis. It makes an effect, partly, via modifing lymphocyte subsets. <h3>Acknowledgements</h3> This research was supported by an investigator-initiated research grant from Pfizer. <h3>Disclosure of Interest</h3> None declared.
P085 Activated memory T cells produce ligands that cause NF-ΚB-dependent inflammatory activation of the endothelium
Authors: KC Jeucken, JP van Hamburg, SW Tas
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Student for a master or a PhD. <h3>Introduction</h3> Endothelial cells (EC) are important contributors to inflammation via expression of inflammatory mediators, including chemokines and adhesion molecules. Production of these inflammatory mediators can be induced via canonical and NF-κB-inducing kinase (NIK)-dependent noncanonical NF-κB signalling. The ligands activating these pathways are well studied, but less is known about the cells producing ligands that can activate NF-κB signalling in EC. <h3>Objectives</h3> To study the effects of soluble factors produced by activated memory T (T<sub>m</sub>) cells on NF-κB dependent inflammatory activation of EC. <h3>Methods</h3> CD4<sup>+</sup>CD45RO<sup>+</sup> Memory T cells were isolated from healthy PBMC using MACS sorting and cultured in medium containing anti-CD3 and anti-CD28 for 72 hour, after which supernatant was harvest. Human umbilical cord EC (HUVEC) were stimulated with 50% T<sub>m</sub> supernatant (T<sub>m</sub> sup). After 72 hour of T<sub>m</sub> sup stimulation HUVEC protein and RNA was harvest and NF-κB signalling and downstream expression of inflammatory mediators was analysed using qPCR and Western Blot. Culture supernatant was analysed by ELISA to detect presence of inflammatory mediators. To repress canonical NF-κB signalling an inhibitor of IKKβ (iIKKβ) was used and to repress NIK-dependent NF-κB signaling an inhibitor of NIK (iNIK) was used. <h3>Results</h3> Stimulation with T<sub>m</sub> sup led to activation of both canonical NF-κB signalling, indicated by increased levels of phosphorylated (p)-IκBα, and noncanonical NF-κB signalling, indicated by increased p100 to p52 processing. HUVEC stimulated with T<sub>m</sub> sup had increased mRNA levels of all tested inflammatory mediators compared to non-treated cells. Gene expression of chemokines (CXCL1, CXCL5, IL6, IL8 and GM-CSF) after T<sub>m</sub> sup stimulation was significantly reduced after treatment with iIKKβ and to a lesser, but still significant, extent after treatment with iNIK. Interestingly, treatment with iIKKβ also led to a reduction in mRNA levels of the adhesion molecules VCAM-1 and ICAM-1, while this effect was minimal after iNIK treatment. In addition, treatment with either IKKβ or iNIK led to a significant reduction in CXCL5 in the culture supernatant of HUVEC stimulated with T<sub>m</sub> sup. <h3>Conclusions</h3> This study provides new insights into the cellular interactions leading to production of inflammatory mediators by EC. Our findings demonstrate that activated T<sub>m</sub> cells factors produce factors that can cause NF-κB-dependent inflammatory activation of EC. Targeting canonical NF-κB signaling and, although to a lesser extent, NIK-dependent NF-κB signaling reduces inflammatory activation of the endothelium. <h3>Disclosure of Interest</h3> None declared.
Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study
Authors: Raúl U Hernández-Ramírez, Li Qin, Haiqun Lin, Wendy Leyden, Romain S Neugebauer, Keri N Althoff, Chad J Achenbach, Nancy A Hessol, Gypsyamber D'Souza, Kelly A Gebo, M John Gill, Surbhi Grover, Michael A Horberg, Jun Li, W Christopher Mathews, Angel M Mayor, Lesley S Park, Charles S Rabkin, Kate Salters, Amy C Justice, Richard D Moore, Eric A Engels, Michael J Silverberg, Robert Dubrow, Adrian Betts, John T. Brooks, Aimee M. Freeman, Stephen E. Van Rompaey, Ann Burchell, Benita Yip, Bin You, Brenna Hogan, Chris Grasso, Robert S. Hogg, Constance A. Benson, Daniel R. Drozd, Timothy R. Sterling, David Haas, Elizabeth Humes, Heidi M. Crane, James Willig, Joseph J. Eron, Jeffrey N. Martin, Michael S. Saag, Jerry Jing, Jinbing Zhang, Joanne Lindsay, Robert F. Hunter-Mellado, Steven G. Deeks, Julia Zhu, Julio S.G. Montaner, Justin McReynolds, Karyn Gabler, Kate Buchacz, Benigno Rodriguez, Jennifer E. Thorne, Joseph B. Margolick, Kathryn Anastos, Lisa P. Jacobson, Marina B. Klein, Abigail Kroch, Liz Morton, Megan Turner, David Fiellin, Stephen J. Gange, Michael J. Mugavero, P. Richard Harrigan, Peter Rebeiro, Ronald J. Bosch, Gregory D. Kirk, Kenneth H. Mayer, Rosemary G. McKaig, Sally Coburn, Sonia Napravnik, Mari M. Kitahata, William B. Lober, Jennifer S. Lee
Journal: The Lancet HIV (2019)
A mobile device application to reduce medication errors and time to drug delivery during simulated paediatric cardiopulmonary resuscitation: a multicentre, randomised, controlled, crossover trial
Authors: Johan N Siebert, Frédéric Ehrler, Christophe Combescure, Christian Lovis, Kevin Haddad, Florence Hugon, Fanny Luterbacher, Laurence Lacroix, Alain Gervaix, Sergio Manzano, Mario Gehri, Corinne Yersin, Daniel Garcia, Franziska Hermann Marina, Cosette Pharisa, Monika Spannaus, Laurence Racine, Bernard Laubscher, Carole Vah, Juan Llor, Aude Juzan
Journal: The Lancet Child & Adolescent Health (2019)
Myocardial Strain in the Assessment of Patients With Heart Failure
Authors: Thomas H. Marwick, Sanjiv J. Shah, James D. Thomas
Journal: JAMA Cardiology (2019)

The cornerstones of imaging in heart failure (HF) are the measurement of systolic and diastolic function and left ventricular (LV) filling pressure.Ejection fraction and the assessment of LV filling pressure and diastolic dysfunction using the ratio of early transmitral flow and LV relaxation (E/e') are conventional imaging markers of LV function. Despite their extensive use in HF guidelines, both have significant detractions, especially in an era when HF with preserved ejection fraction is becoming the dominant presentation. In contrast, strain imaging has provided a new window into myocardial mechanics. Myocardial strain is now well validated, robust, and can easily be performed on most modern echocardiography machines. This Review summarizes the evidence in 9 situations across the stages of HF where LV global longitudinal strain and other strain parameters may provide information on risk prediction, diagnosis, assessment of treatment response, and follow-up.The evolution of myocardial deformation imaging from research tool to clinical practice will provide clinicians with a useful additional imaging parameter to facilitate the assessment and risk evaluation of patients with HF.
Colorectal cancer screening barriers.
Authors: Monaliben Patel, Jessica Malin, Anna Headly
Journal: Journal of Clinical Oncology (2012)

e14175 Background: Colorectal cancer is the third cause of cancer death in the U.S., yet only 53% of adults over 50 are screened. Rates for minorities and patients without a high school education are lower. Colonoscopy may prevent 65% of cancers; identifying obstacles to screening could save lives. Our objective was to investigate obstacles and improve screening in Camden, NJ, a city that is 95% minority, only half of adults have completed high school, and 44% of families live below poverty level. Methods: In coordination with the American Cancer Society and Horizon Medicaid, we obtained data on Horizon enrollees at a primary care practice of Cooper University Hospital in Camden. All patients 50 and above with no insurance claims for screening in the last 10 years were included. 92 patients met criteria. We attempted to contact each by phone (via interpretation service if Spanish speaking). A standardized template was used to explain benefits of screening, ask for reasons for not having screening, offering transportation to the procedure, and asking if they were willing to have a colonoscopy. Patients who agreed were scheduled for colonoscopy. Results: 92 patients were identified. 30 could not be contacted after 3 attempts. Of 62 contacted, 12 agreed to colonoscopy; 25 stated they had already had screening; and 25 declined. Of 12 who agreed, reasons for not having had screening were: lack of awareness (6 patients, 5 Spanish speaking); not having transportation (3, 1 Spanish); and simply having put it off (3). Of 25 who declined, reasons were: desire to schedule themselves (8); the subject was too uncomfortable (4); mistrust of doctors (1); and being too scared (1). 10 (7 Spanish) gave no reason, and 1 had moved. Conclusions: Obstacles identified to colorectal screening were 1) lack of awareness (50% of patients who agreed to procedure); 2) transportation (25% of patients who agreed); 3) language barriers (83% of those who were unaware of recommendations were Spanish speaking); 4) fear/mistrust (8%); and 5) having lost contact with the system (33%). Efforts toward increasing screening should be targeted accordingly. We acknowledge the ACS and the Walmart Foundation for their participation and support. Findings and conclusions do not necessarily represent the views of ACS and the Walmart Foundation.
Digital biomarkers of mood disorders and symptom change
Authors: Nicholas C. Jacobson, Hilary Weingarden, Sabine Wilhelm
Journal: npj Digital Medicine (2019)

Current approaches to psychiatric assessment are resource-intensive, requiring time-consuming evaluation by a trained clinician. Development of digital biomarkers holds promise for enabling scalable, time-sensitive, and cost-effective assessment of both psychiatric diagnosis and symptom change. The present study aimed to identify robust digital biomarkers of diagnostic status and changes in symptom severity over ~2 weeks, through re-analysis of public-use actigraphy data collected in patients with major depressive or bipolar disorder and healthy controls. Results suggest that participants' diagnostic group status (i.e., mood disorder, control) can be predicted with a high degree of accuracy (predicted correctly 89% of the time, kappa = 0.773), using features extracted from actigraphy data alone. Results also suggest that actigraphy data can be used to predict symptom change across ~2 weeks (r = 0.782, p = 1.04e-05). Through inclusion of digital biomarkers in our statistical model, which are generalizable to new samples, the results may be replicated by other research groups in order to validate and extend this work.
Effective Lipidoid Nanoparticle Delivery In Vivo of siRNA Targeting Kappa Light Chain Production in a Murine Xenograft Model
Authors: Xun Ma, Ping Zhou, Adin Kugelmass, Denis Toskic, Melissa Warner, Lisa X. Lee, Teresa Fogaren, Ming Wang, Yamin Li, Liu Yang, Qiaobing Xu, Raymond Comenzo
Journal: Blood (2018)
Effects of a folic acid 5 mg daily intervention on markers of vitamin B status and kynurenine pathway
Authors: Guilherme Wataru Gomes, Maylla Rodrigues Lucena, Per Magne Ueland, Oivind Midttun, Clovis Paniz, Juliano Felix Bertinato, Cecilia Zanin Palchetti, Elvira Maria Guerra-Shinohara
Journal: Blood (2017)
Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient
Authors: Afshin Beheshti, Kristen E. Stevenson, Ravi Dashnamoorthy, Charles Vanderburg, David M Weinstock, Andrew M. Evens
Journal: Blood (2018)
Abstract OT3-04-05: Measuring the impact of MammaPrint on treatment in breast cancer patients: A prospective registry (IMPACt)
Authors: H Soliman, S Untch, L Blumencranz
Journal: Cancer Research (2017)

Abstract This abstract was not presented at the symposium. Citation Format: Soliman H, Untch S, Blumencranz L. Measuring the impact of MammaPrint on treatment in breast cancer patients: A prospective registry (IMPACt) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-04-05.
Bipolar disorder: most patients receive suboptimal treatment, finds Scottish study
Authors: Susan Mayor
Journal: BMJ (2019)

A quarter of patients with bipolar disorder in Scotland are treated with antidepressant monotherapy and do not receive lithium as recommended by the National Institute for Health and Care Excellence (NICE), a national data linkage study has shown.1

“Our findings suggest that most patients with bipolar disorder in Scotland are missing out on optimal treatments such as lithium and that many are receiving treatments such as antidepressant monotherapy that are at best ineffective and, at worse, detrimental for long term outcome,” warned the study authors, led by Daniel Smith, professor of psychiatry at …
A Correction to the Research Article Titled: "Reversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens" by Brian Alexander, Jennifer Warner-Schmidt, Therese Eriksson, Carol Tamminga, Margarita Arango-Llievano, Subroto Ghose, Mary Vernov, Mihaela Stavarche, Sergei Musatov, Marc Flajolet, Per Svenningsson, Paul Greengard, Michael G. Kaplitt
Journal: Science Translational Medicine (2010)
Abstract 2567: CYP24A1-induced vitamin D insufficiency promotes breast cancer growth
Authors: Makoto Osanai, Akira Takasawa, Kumi Takasawa, Masaki Murata, Norimasa Sawada
Journal: Cancer Research (2017)

Abstract Vitamin D plays a critical role in the maintenance of tissue homeostasis by regulating the expression of genes affecting cell proliferation, differentiation, and apoptosis. The vitamin D 24-hydroxylase CYP24A1 functions in vitamin D target tissues to degrade the hormonal form of vitamin D. Existing knowledge regarding dysregulated CYP24A1 expression supports its candidacy as a putative oncogene. In our presentation, we demonstrate that the suppression of constitutive CYP24A1 expression by CYP24A1-specidic shRNA conferred target cells with increased susceptibility to apoptosis and consequently inhibited anchorage-independent growth in breast carcinoma cells. In addition, suppression of vitamin D metabolism following knockdown of CYP24A1 significantly reduced tumor growth in vivo. Since these data provide substantial evidence for a pro-survival and stimulatory oncogenic effect of CYP24A1 in breast carcinoma cells, we will discuss the potential feasibility of CYP24A1-inhibitory cancer therapies. Citation Format: Makoto Osanai, Akira Takasawa, Kumi Takasawa, Masaki Murata, Norimasa Sawada. CYP24A1-induced vitamin D insufficiency promotes breast cancer growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2567. doi:10.1158/1538-7445.AM2017-2567
Postoperative Endothelial Cell Density Is Associated with Late Endothelial Graft Failure after Descemet Stripping Automated Endothelial Keratoplasty
Authors: Sanjay V. Patel, Jonathan H. Lass, Beth Ann Benetz, Loretta B. Szczotka-Flynn, Nathan J. Cohen, Allison R. Ayala, Maureen G. Maguire, Donna C. Drury, Steven P. Dunn, Bennie H. Jeng, Marc F. Jones, Harry J. Menegay, Matthew S. Oliva, George O.D. Rosenwasser, John A. Seedor, Mark A. Terry, David D. Verdier
Journal: Ophthalmology (2019)
ECG Challenge: April 15, 2014
Authors: Philip Podrid
Journal: Circulation (2014)

ECG Challenge 1617A 78-year-old woman with a history of atrial fibrillation who is taking Coumadin for the prevention of embolism and a β-blocker and digoxin for rate control presents to her primary care physician with concerns of fatigue and lightheadedness that have been present for several days.What is the diagnosis?To submit your diagnosis, go to http://circ.ahajournals.
British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018
Authors: F.M. Lewis, F.M. Tatnall, S.S. Velangi, C.B. Bunker, A. Kumar, F. Brackenbury, M.F. Mohd Mustapa, L.S. Exton, P.M. McHenry, T.A. Leslie, S. Wakelin, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, N. Chiang, F.S. Worsnop, D. Buckley, G. Petrof, A. Salin, N. Callachand, C. Saunders, A.A. Salad
Journal: British Journal of Dermatology (2018)

Abstract Linked Comment: Akel and Fuller. Br J Dermatol 2018; 178:823–824. Plain language summary available online
Sphincterotomy plus balloon dilation versus sphincterotomy alone for choledocholithiasis: a meta-analysis
Authors: Shou Quan Dong, Tikka Prabhjot Singh, Qiu Zhao, Juan Juan Li, Hong Ling Wang
Journal: Endoscopy (2019)

Abstract Background Endoscopic sphincterotomy plus balloon dilation (ESBD) is considered to be a promising method for the removal of large common bile duct (CBD) stones. However, when compared with endoscopic sphincterotomy (EST) alone, the efficacy and safety of ESBD remain controversial. This meta-analysis aimed to compare the efficacy and safety of ESBD vs. EST for the removal of large CBD stones. Methods Electronic databases were searched up to 15 July 2018 for literature that compared ESBD with EST for the removal of CBD stones. Pooled odds ratios (ORs) of the stone clearance rate and the complication rate were used to compare the efficacy and safety of ESBD vs. EST. Results A total of 18 studies with 2789 patients were included. The results showed that the stone removal rate was much higher in the ESBD group than in the EST group, both across all endoscopic retrograde cholangiopancreatography (ERCP) sessions (OR 2.68, 95 % confidence interval [CI] 1.79 to 4.01) and during the first ERCP session (OR 2.07, 95 %CI 1.37 to 3.12). The ESBD group had fewer complications than EST alone (OR 0.63, 95 %CI 0.47 to 0.85). Moreover, the ESBD group needed less mechanical lithotripsy (OR 0.38, 95 %CI 0.24 to 0.61) and had a shorter procedure time (mean difference – 4.05, 95 %CI – 7.02 to – 1.09) than EST alone. Conclusion The efficacy and safety of ESBD were superior to those of EST for the removal of large CBD stones. Moreover, less mechanical lithotripsy and shorter procedure times were needed with ESBD to manage large stones.
Oocyte Cryopreservation in a Transgender Male Adolescent
Authors: Stephanie S Rothenberg, Selma F Witchel, Marie N Menke
Journal: New England Journal of Medicine (2019)

Oocyte Cryopreservation in a Transgender Youth Multiple medical societies endorse preservation of fertility in persons who identify as transgender. A multidisciplinary approach to oocyte cryopreser...